Compare STEX & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEX | RNXT |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.5M | 79.4M |
| IPO Year | 2013 | 2021 |
| Metric | STEX | RNXT |
|---|---|---|
| Price | $0.63 | $1.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $9.00 | $8.25 |
| AVG Volume (30 Days) | 870.3K | ★ 1.4M |
| Earning Date | 05-17-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | N/A | ★ N/A |
| Revenue | $18,000.00 | ★ $1,123,000.00 |
| Revenue This Year | N/A | $194.66 |
| Revenue Next Year | $1,044.81 | $279.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $0.57 | $0.70 |
| 52 Week High | $7.19 | $2.59 |
| Indicator | STEX | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 39.52 | 51.22 |
| Support Level | N/A | $0.83 |
| Resistance Level | $1.07 | $2.59 |
| Average True Range (ATR) | 0.05 | 0.26 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 23.69 | 13.46 |
Streamex Corp is a vertically integrated technology and infrastructure company. The Company is a technology company with two principal lines of business: (i) Tokenized Asset Finance, focused on digital asset and real-world asset tokenization via Streamex Exchange platform, and (ii) Biomedical Technology, focused on signal processing solutions in electrophysiology. The group provides institutional-grade solutions that bring traditional commodities and assets on-chain through secure, regulated, and yield-bearing financial instruments. It is committed to delivering transparent, scalable, and compliant digital asset solutions that bridge the gap between traditional finance and blockchain-enabled markets.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.